03.05.15
A study published in Digestive and Liver Disease foundthe probiotic yeast Saccharomyces cerevisiae CNCM I-3856 demonstrated a significant effect in improving abdominal pain and discomfort in individuals with Irritable Bowel Syndrome (IBS). The patented probiotic yeast from Lesaffre’s collection is marketed under the commercial name of Lynside Pro GI+.
A randomized double-blind placebo-controlled study assessed the effect of CNCM IÂ3856 on digestive discomfort and abdominal pain in subjects with IBS. Two hundred volunteers were treated with either 500mg/day of Saccharomyces cerevisiae CNCM IÂ3856or a placebo.
Results of the study show a significant improvement in bowel pain and discomfort after 4 weeks of administration in 63% of subjects receiving the strain Saccharomyces cerevisiae CNCM I-3856 compared to 47% in the placebo group (p=0.04). In addition, “the consumption of this probiotic yeast was well tolerated and the analgesic effect observed was not mitigated by any adverse side effects,” explained Prof. Pierre Desreumaux, the study’s supervisor and an international specialist of Inflammatory Bowel Disease from University of Lille (France). In addition, he noted “These results suggest that Saccharomyces cerevisiae CNCM I-3856 may be a new safe strategy to improve abdominal pain and discomfort in patient suffering from IBS symptoms”; adding that “even long term treatments could be contemplated considering the absence of side effects.”
For more information: www.lesaffrehumancare.com
A randomized double-blind placebo-controlled study assessed the effect of CNCM IÂ3856 on digestive discomfort and abdominal pain in subjects with IBS. Two hundred volunteers were treated with either 500mg/day of Saccharomyces cerevisiae CNCM IÂ3856or a placebo.
Results of the study show a significant improvement in bowel pain and discomfort after 4 weeks of administration in 63% of subjects receiving the strain Saccharomyces cerevisiae CNCM I-3856 compared to 47% in the placebo group (p=0.04). In addition, “the consumption of this probiotic yeast was well tolerated and the analgesic effect observed was not mitigated by any adverse side effects,” explained Prof. Pierre Desreumaux, the study’s supervisor and an international specialist of Inflammatory Bowel Disease from University of Lille (France). In addition, he noted “These results suggest that Saccharomyces cerevisiae CNCM I-3856 may be a new safe strategy to improve abdominal pain and discomfort in patient suffering from IBS symptoms”; adding that “even long term treatments could be contemplated considering the absence of side effects.”
For more information: www.lesaffrehumancare.com
